11.05
-1.14(-9.35%)
Currency In USD
| Previous Close | 12.19 |
| Open | 12.27 |
| Day High | 12.66 |
| Day Low | 10.87 |
| 52-Week High | 14.22 |
| 52-Week Low | 4.63 |
| Volume | 85,615 |
| Average Volume | 129,620 |
| Market Cap | 50.42M |
| PE | -14.93 |
| EPS | -0.74 |
| Moving Average 50 Days | 9.15 |
| Moving Average 200 Days | 6.87 |
| Change | -1.14 |
If you invested $1000 in Tenax Therapeutics, Inc. (TENX) 10 years ago, it would be worth $0.11 as of January 05, 2026 at a share price of $11.05. Whereas If you bought $1000 worth of Tenax Therapeutics, Inc. (TENX) shares 5 years ago, it would be worth $3.73 as of January 05, 2026 at a share price of $11.05.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
GlobeNewswire Inc.
Dec 17, 2025 2:16 PM GMT
Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of 2026 Global Phase 3 LEVEL-2 Study Initiated; Compan
Tenax Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 25, 2025 12:00 PM GMT
CHAPEL HILL, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary thera
Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF
GlobeNewswire Inc.
Nov 06, 2025 12:00 PM GMT
CHAPEL HILL, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary thera